Physician profile
Saurabh Khurana
NPI 1851656292
$3,166.35
in general payments reported to CMS, 2019-2025
21 companies · $2,316 in 2025
The $2,316 reported for 2025 was more than what 98% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $305 · 2023: $16.37 · 2024: $529 · 2025: $2,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Travel and Lodging: $748 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.42 |
| Travel and Lodging | $748.21 |
| Education | $322.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,559.08 | 2025 | |
| Abbott Laboratories | $272.58 | 2025 | Ensite |
| Novo Nordisk INC | $248.21 | 2022-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $143.19 | 2022 | |
| Steris Corporation | $141.55 | 2024 | |
| Esperion Therapeutics, INC. | $136.82 | 2024-2025 | Nexletol, Nexlizet |
| Boston Scientific Corporation | $126.08 | 2024-2025 | Watchman Flx, Enroute Transcarotid Stent, Lux-Dx Insertable Cardiac Monitor |
| United Therapeutics Corporation | $98.02 | 2024-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.90 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.97 | 2024-2025 | Lifevest |
| Penumbra, INC. | $57.83 | 2025 | Indigo System |
| W. L. Gore & Associates, INC. | $50.00 | 2025 | Gore-Tex Vascular Graft |
| Regeneron Healthcare Solutions, INC. | $32.94 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $31.87 | 2025 | Eliquis, Camzyos |
| Abiomed | $25.98 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.53 | 2022 | |
| Pfizer INC. | $20.40 | 2025 | |
| Bridgebio Pharma, INC. | $19.97 | 2025 | Attruby |
| Grifols USA, LLC | $19.34 | 2025 | Prolastin-C Liquid |
| Chiesi USA, INC. | $17.72 | 2024 | Kengreal, Cleviprex |
| Astrazeneca Pharmaceuticals Lp | $16.37 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Khurana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.